Tesaro Explained
Tesaro Inc. is a pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer.
History
Tesaro was founded in 2010.[1] The company's first commercial product, Varubi, was approved by the FDA in October 2015.[2] As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD.[3] The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA. In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer.[4] On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale.[4] On December 3, 2018, GSK announced it would acquire the company for $5.1 billion,[5] and the deal was completed on January 22, 2019.[6]
Products under development
- Rolapitant – intravenous form in phase III clinical trials for use in chemotherapy-induced nausea and vomiting
- Niraparib – PARP inhibitor in clinical trials for breast and ovarian cancer.[7]
- TSR-042
- TSR-022
- Dostarlimab – In February 2023, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.
Notes and References
- Web site: Tesaro . FierceBiotech . 2017-02-25.
- Web site: TESARO - Quarterly Report . Ir.tesarobio.com . 2017-02-25.
- Web site: TESARO - Annual Report . Ir.tesarobio.com . 2017-02-25.
- News: D. Rockoff . Jonathan . Cimilluca . Dana . May 31, 2017 . Tesaro Explores Sale . . New York City, New York . June 1, 2017 .
- Web site: GSK slides after buying cancer firm Tesaro for hefty $5.1 billion. 3 December 2018. uk.reuters.com.
- Web site: GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company. 22 January 2019.
- Web site: 2016 Press Release: Niraparib Significantly Improves Outcome of Ovarian Cancer Patients in Landmark Trial . ESMO . 2017-02-25.
